Neurotrope — Investor Presentation (January 2014)
22 slides from Neurotrope's investor presentation, Jan 13, 2014
Slide 1: Targeting the Treatment of Alzheimer's Disease and other Neurodegenerative Diseases
Targeting the Treatment of Alzheimer’s Disease and other Neurodegenerative Diseases www.neurotropebioscience.com January 2014
Slide 2: Safe Harbor Statement
Safe Harbor Statement Cautionary language regarding forward - looking statements Certain statements in this presentation, particularly those pertaining to our strategy, constitute forward - looking statements. Such statements are based upon the current beliefs and expectations of management and are
Slide 3: Neurotrope, Inc. (OTCQB: NTRP)
Neurotrope, Inc. (OTCQB: NTRP) • A clinical development stage, publicly - traded diagnostic and pharmaceutical company • Capital invested in technology to - date approaching $100 mm (by BRNI) over 13 years across ongoing R & D investment, facilities / infrastructure, and intellectual property (IP ).
Slide 4: Neurotrope BioScience, Inc. History
Neurotrope BioScience , Inc. History • October 2012 - Company Formed • February 2013 – Technology and Product Licenses transfer from BRNI to Neurotrope ; hires Dr. James New as CEO; closes $10.4 million Series A preferred stock capital raise • February to August 2013 - Establishes business plans to
Slide 5: Management Team
Management Team • Dr. James New – Chief Executive Officer • Pfizer, Inc. - Senior Director of Licensing • Novartis - Director M&A and Head of Worldwide Business Development • Abrika Pharma., Lifecycle Pharma., AIKO Biotechnology – CEO • Dr. John Abeles – Chairman • Physician and pharmacologist • Fou
Slide 6: Trading, Ownership & Capitalization
Trading, Ownership & Capitalization Current Capitalization Shares Common Stock 21.7 MM Series A Convertible Preferred Stock (Convertible @ $1.00 / share) 23 .0 MM Options & Warrants Outstanding ( Wtd . Avg. E.P. $0.80 / share) 8.5 MM Total fully diluted shares 53.2 MM Trading, Ownership, Financials
Slide 7: Opportunity: Target Alzheimer's Disease Early
Opportunity Target Alzheimer’s Disease Early with an Effective Drug and New Mechanism Delay the Disease Progression Estimated $15 - $20 BN in Annual Worldwide Sales 7
Slide 8: Industry's Product Development Efforts in the Alzheimer's Field
81 11 2 5 Number Of Products In Development Categories The Industry’s Product Development Efforts in the Alzheimer’s Field From 2012 Report “ Medicines in Development” Alzheimer’s Disease PHRMA Report 8
Slide 9: Past Efforts in Developing Drugs for AD have focused on Beta Amyloid
Past Efforts in Developing Drugs for AD have focused on Beta Amyloid 9
Slide 10: Current Themes Dominating AD Research
Current Themes Dominating AD Research Early Diagnosis Biomarker Analysis Disease Modifying Therapy Critical to early detection of AD pathology Allows treatment with a potentially wider range of current and future therapeutics Stemming disease progression would represent a breakthrough therapy Neurot
Slide 11: Impact of a 5-year Delay in the Onset of AD on Costs
Delayed Onset Current Trajectory Cost in Billions of Dollars Impact of a 5 - year delay in the Onset of AD on Costs Americans Age 65+ with Alzheimer’s Disease 2010 - 2050 Source: Alzheimer’s Association, “Changing the Trajectory of Alzheimer’s Disease: A National Imperative” May 2010 2010 2050 2020
Slide 12: Core Technology is PKC Activation
• New drug prototypes have been identified which activate Protein Kinase C (PKC ) in a highly selective manner - Bryostatin • “ Turning - on” PKC has been shown to “re - boot” neurons in various animal models • Neuronal regeneration occurs due to the fresh expression of proteins critical to the main
Slide 13: PKC Therapeutics provide Neuroprotection through a Multi-Modal Approach
PKC Therapeutics provide Neuroprotection through a Multi - Modal Approach − Anti A β − Anti Ʈ - phosphorylation, and − Anti apoptosis/ or prevention of cell death through activation of Akt 13
Slide 14: Profile of Bryostatin vs. other AD Drugs
Profile of Bryostatin vs. other AD Drugs Neurotrope’s drug prototype shows activity in a wide panel of test systems where other FDA approved drugs ( Donepezil ) or experimental drugs ( bapineuzumab ) have failed. 14
Slide 15: Competitive Advantage: Two Lead Drug Candidates
Competitive Advantage Two Lead Drug Candidates: Bryostatin and DHA - CP6 • Bryostatin – First lead drug candidate • Natural product isolated from a marine organism • Developed as an anticancer drug • Has been evaluated in 63 clinical studies; > 1,200 cancer patients • Well established safety, pharma
Slide 16: Drug Development Pipeline
Drug Development Pipeline 16
Slide 17: Neurotrope's Alzheimer's Diagnostic System
Neurotrope’s Alzheimer’s Diagnostic System ( proposed Brand Name for the Diagnostic Test ) 17
Slide 18: Three Steps to Processing the Biopsy Sample for Alzheimer's Diagnostics
Physician’s Office Taking the Biopsy Sample Packaging & Mailing the sample to Neurotrope BioScience Neurotrope’s Testing Laboratory in Rockville, Maryland Three Steps to Processing the Biopsy Sample for Alzheimer’s Diagnostics 2 1 3 18
Slide 19: Three Different Peripheral Biomarkers are Monitored for AD Detection
Three Different Peripheral Biomarkers are Monitored for AD Detection • Patient / Clinician provides a skin biopsy which is shipped to Neurotrope • The skin biopsy is used to: • Grow cultured fibroblasts in tissue culture • Analyzed for levels of PKC ε • Analyzed for the ratio of ERK 1/2 concentratio
Slide 20: Near Term Milestones in the Development of our AD Dx
1Q 2015 2Q 2014 2Q 2015 3Q 2015 3Q 2014 4Q2014 1Q 2014 Ongoing prospective clinical validation trial in 150 patients Technology Transfer to a 3 rd party Laboratory Study completes Near Term Milestones in the Development of our AD Dx Commercial Launch 20
Slide 21: Conclusions: The Power of Teaming an AD Diagnostic with an AD Therapeutic
Conclusions: The Power of Teaming an AD Diagnostic with an AD Therapeutic Potential for Early and Accurate Diagnosis Potential for Early Therapeutic Intervention Delaying AD Progression A Paradigm Shift in the Treatment and Management of AD • Near term monetization of AD Dx • Enrichment of clinical
Slide 22: Contact Information
Contact Information Additional Information about Neurotrope , Inc. may be obtained by contacting: The Company: www.neurotropebioscience.com Dr. James New 954.632.6630 [email protected] Robert Weinstein 914.295.2765 [email protected] Investor Relations: Tony Schor Invest